Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Rehydra+ Wellness

CoreAge Rx
Site position #1

Higher grade

Rehydra+ Wellness
Site position #421

Lower grade

The verdict

CoreAge Rx takes it — 89.5/100 to 58.5/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoreAge Rx +31
92
61
Dose & formulationCoreAge Rx +34
88
54
Clinical oversightCoreAge Rx +22
93
71
Labs & monitoringCoreAge Rx +38
90
52
FulfillmentCoreAge Rx +22
95
73
Contract termsCoreAge Rx +46
67
21
CoreAge Rx · top barRehydra+ Wellness · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxRehydra+ Wellness
WeighScore89.5/10058.5/100
GradeB+C
Site position#1#421
Semaglutide$99/mo$119/mo (Tier 1 on a six-month membership the site calls non-cancelable; a one-time four-week vial is $149)
Tirzepatide$149/mo$169/mo (Tier 1 on a six-month membership the site calls non-cancelable; a one-time four-week vial is $219)
CoverageAll 50 states19 states (the site elsewhere says 20)
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
CoreAge Rx

Site position #1 · B+

Strengths

  • Advertises the same medication price at every dose
  • Semaglutide and tirzepatide injection options
  • No membership fee; standard prescription shipping included unless checkout states otherwise

Where it loses points

  • Compounded only; no FDA-approved brand option listed
  • Dispensing pharmacy not identified on the reviewed product pages
  • Applicable $50–$100 consultation fee is nonrefundable after review begins
  • Orders become final after approval and pharmacy transmission; 30-day refund cutoff also applies
Rehydra+ Wellness

Site position #421 · C

Strengths

  • Names a medical director and a nurse practitioner, plus the practice's owner and CFO, which is more disclosure than most of this ranking offers
  • Names Olympia Pharmacy on the semaglutide product page
  • Sells one-time four-week vials alongside the memberships, so a reader can buy without committing
  • Free shipping and a free consultation are stated, with no membership fee on the one-time route

Where it loses points

  • No month-to-month plan exists: the $119 and $169 figures are tiers on a six-month membership, and the nearest standing price is a one-time four-week vial at $149 or $219
  • The memberships page calls the plan non-cancelable and locked in for six months; section 7 of the Terms says the subscription can be canceled at any time before the next billing cycle
  • The site does not say what happens after the six months — renewal price, automatic renewal or termination
  • Every “normal price” anchor on the memberships page sits above the site's own cash price for the same dose
  • The state count contradicts itself: 19 states are named on the weight-loss page, 20 is claimed on the homepage and About page, and the About page also says across the country
  • The Terms and shipping pages print a phone number that differs by one digit from the number on every other page, and the contact page gives an entity suffix that is not a Texas entity type
  • No compounding class appears anywhere, and the tirzepatide pages name no pharmacy
  • Prescription sales are final, with no returns

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard